TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03103152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Aspirin & Vitamin D
Description: Aspirin 1 x 300mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Aspirin, Vitamin D placebo
Description: Aspirin 1 x 300mg tablet daily \& Vitamin D placebo (8 drops).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Aspirin , Vitamin D
Description: Aspirin 1 x 100mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Aspirin , Vitamin D
Description: Aspirin 1 x 100mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Aspirin, Vitamin D placebo
Description: Aspirin 1 x 100mg tablet daily \& Vitamin D placebo 8 drops daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Placebo, Vitamin D
Description: Aspirin 1 x 300mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin placebo, Vitamin D placebo
Description: Aspirin 1 x 100mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin placebo, Vitamin D placebo
Description: Aspirin 1 x 100mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
Study: NCT01780090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad software
Description: A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
Study: NCT04560595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caffeine Reduction Manual
Description: We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caffeine Reduction Manual
Description: We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.
Study: NCT04515654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDEAS (Identity Evolution and Sharing) Performance
Description: 60 minute webinar depicting first-hand stories of transgender and gender non-conforming individuals followed by expert panel/talk-back
Study: NCT04973150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children.
Description: To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children. Methods A total of 300 preschool-age children who underwent general anesthesia of selective ophthalmic surgery in a 3A grade hospital from August 2019 to July 2020 were selected as the research object, who were divided into experimental group and control group with 150 cases each by random number table. Children in the control group received regular education on cartoon animation videos before surgery; children in the experimental group received eye-covering pretreatment on the basis of cartoon animation videos. The differences in preoperative anxiety degree score, postoperative acute delirium incidence, delirium degree score, and postoperative nursing care difficulty score were compared between the two groups.
Study: NCT02445638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole egg
Description: Subjects will be provided with the equivalent of 2 whole eggs daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yolk-free egg
Description: Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
Study: NCT00751062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhXA41
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
Study: NCT04722705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional Er:YAG laser
Description: At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed 2,940 nm Er:YAG fractional laser. (long pulse mode, 1500mJ, 2Hz, 2 pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional Er:YAG laser
Description: At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed 2,940 nm Er:YAG fractional laser. (long pulse mode, 1500mJ, 2Hz, 2 pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulse light
Description: At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed IPL. (irridation energy: 12.5J/cm2, pulse duration: 10ms, 1pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment.
Study: NCT03039764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapael
Description: This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
Study: NCT01661335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron, dexamethasone, aprepitant
Description: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron, Dexamethasone, placebo
Description: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
Study: NCT04934813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: application of different bone graft and sealing means after tooth extraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: application of different bone graft and sealing means after tooth extraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: application of different bone graft and sealing means after tooth extraction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: application of different bone graft and sealing means after tooth extraction
Study: NCT03885895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injectable Product
Description: Ampoules used for intradermal injection
Study: NCT01076569

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04490746

Intervention type: OTHER
Intervention: with no intervention, Collect samples
Description: only with observation,there is no need to intervene

Intervention type: OTHER
Intervention: with no intervention, Collect samples
Description: only with observation,there is no need to intervene

Intervention type: OTHER
Intervention: with no intervention, Collect samples
Description: only with observation,there is no need to intervene
Study: NCT02421614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-protein low-carbohydrate diet with high olive oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-protein low-carbohydrate diet with high sunflower oil
Study: NCT03885895

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q switched KTP (532nm)
Description: LASER
Study: NCT01464593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyso-Thermosensitive Liposomal Doxorubicin
Description: Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% Dextrose Solution
Description: Single 30 minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox
Description: ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
Study: NCT01631539

Intervention type: DEVICE
Group type: OTHER
Intervention: DC Bead™
Description: chemoembolization with DC Bead™ loaded with Irinotecan

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: 400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly

Intervention type: DRUG
Group type: OTHER
Intervention: 5 FU
Description: every 2 weeks IV

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: every 4 weeks chemoembolization
Study: NCT03279822

Intervention type: OTHER
Intervention: not any intervention
Description: not any intervention
Study: NCT02802787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camp Discovery
Description: Activities will include physical, social, emotional, sensory and spiritual activities.
Study: NCT02596555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
Study: NCT04110626

Intervention type: OTHER
Intervention: Questionnaires
Description: The questionnaires are completed at the 3 survey times (T0, T1 and T2) by all pupils involved. Collected data are quantitative

Intervention type: OTHER
Intervention: Non-directive Interviews
Description: The interviews are conducted with 80 pupils/year randomly selected (i.e. 2 per class and 8 per establishment/year). Collected data are qualitative
Study: NCT05109533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus BMX 54, Lactobacillus reuteri RC-14, Lactobacillus rhamnosus GR-1
Description: Probiotics implementation
Study: NCT04001725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: A minimum daily dosage of Dexamethasone 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day and 2550 mg daily (maximum dose), oral administration (OS) of Metformin; starting dose will be 850 mg/day, to be progressively increased to 1700 mg/day on day 4 and 2550 mg/day on day 7, if well tolerated.
Study: NCT03364400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT1021
Description: Peptide
Study: NCT01117038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil and enalapril
Description: enalapril twice a day for 11 days avanafil/placebo once a day for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil and amlodipine
Description: amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days
Study: NCT00981812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEM Breast Biopsy
Description: Breast biopsy using PEM guidance and Stereo Navigator software
Study: NCT02923323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI including DTI , EEG, CGMS
Description: Will be connected to continuous simultaneous systems

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI including DTI , EEG, CGMS
Description: Will be connected to continuous simultaneous systems

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive tests
Description: Will perform multiple tests of neurocognitive functions after lunch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive tests
Description: Will perform multiple tests of neurocognitive functions after lunch
Study: NCT00917852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore Conformable TAG Thoracic Endoprosthesis
Description: Endovascular stent graft
Study: NCT04301869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Oral versus intravenous therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Oral versus intravenous therapy
Study: NCT03783819

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypericum perforatum oil
Description: Ointment containing Hypericum perforatum oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ointment containing plant oils used in Hypericum perforatum oil production and dye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLS induced irritation
Description: 60 uL of 1% w/v sodium lauryl sulphate (SLS) will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis. Procedure will be performed to specified skin sites, according to randomization protocol.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SLS induced irritation
Description: 60 uL of 1% w/v sodium lauryl sulphate (SLS) will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis. Procedure will be performed to specified skin sites, according to randomization protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tape-stripping
Description: Skin barrier disruption will be induced by tape-stripping. Procedure will be performed to specified skin sites, according to randomization protocol.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tape-stripping
Description: Skin barrier disruption will be induced by tape-stripping. Procedure will be performed to specified skin sites, according to randomization protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UV radiation
Description: UV radiation will be used to induce skin erythema and damage. Procedure will be performed to specified skin sites, according to randomization protocol.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: UV radiation
Description: UV radiation will be used to induce skin erythema and damage. Procedure will be performed to specified skin sites, according to randomization protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intact skin
Description: Healthy, intact skin. Procedure will be performed to specified skin sites, according to randomization protocol.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intact skin
Description: Healthy, intact skin. Procedure will be performed to specified skin sites, according to randomization protocol.
Study: NCT00375973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine po 60-120 mg/day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill dose comparable to duloxetine
Study: NCT04459325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tigerase® and best available care
Description: Nebulised dornase alfa \[2.5 mg BID\] for 7 days

Intervention type: OTHER
Group type: OTHER
Intervention: Best available care
Description: Patients will receive the usual care in accordance with good practice.
Study: NCT00786929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter drainage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Study: NCT02680054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Asp(B28)-
Description: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Asp(B28)-
Description: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Asp(B28)-
Description: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
Study: NCT04514159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 is the study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib (VERZENIO®) is an approved drug.
Study: NCT04036175

Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen
Description: Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2\>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2\>= 92%

Intervention type: DEVICE
Group type: OTHER
Intervention: High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen
Description: Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2\>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2\>= 92%
Study: NCT00210418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified food rations
Description: The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ \<-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified food rations
Description: The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ \<-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and communication to improve feeding practices
Description: The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and communication to improve feeding practices
Description: The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
Study: NCT04578457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without NR enabled
Description: Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(1)
Description: Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(2)
Description: Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(3)
Description: Each participant will be fitted with a third noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1) and NR(2).
Study: NCT00502541

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Repeat macular grid laser or observation
Study: NCT06254118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyunsaturated Fatty Acids
Description: 1000mg omega-3 fatty acids taken once daily with meals for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: olive oil
Description: 1000mg olive oil taken once daily with meals for 12 months